Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in critically...
Steady State Concentration01:05

Steady State Concentration

A steady state refers to the level of a drug in the body once it has reached an equilibrium between administration and elimination. It represents the point at which the drug administration rate equals the drug elimination rate, resulting in a relatively constant concentration in the body over time. The dynamic equilibrium is crucial to ensure the drug's effectiveness with minimal risk of toxicity.
Most drugs are administered in repeated doses at fixed intervals or through continuous intravenous...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Don't Change Much.

American journal of men's health·2016
Same author

Patient preference and the impact of decision-making aids on prostate cancer treatment choices and post-intervention regret.

Current oncology (Toronto, Ont.)·2013
Same author

Advances in diagnosis and management of prostate cancer.

Canadian family physician Medecin de famille canadien·2011
Same author

Transrectal Ultrasound of Prostatic Carcinoma: A new way to evaluate benign and malignant conditions.

Canadian family physician Medecin de famille canadien·2011
Same author

Preferences for sexual information resources in patients treated for early-stage prostate cancer with either radical prostatectomy or brachytherapy.

BJU international·2004
Same author

Intermittent androgen suppression.

BJU international·2004
Same journal

Predicting Post-Radiotherapy Lymphocyte Recovery for Individualized Risk Stratification in Locally Advanced Esophageal Squamous Cell Carcinoma.

Current oncology (Toronto, Ont.)·2026
Same journal

From Adjunct to Essential: Integrating Supportive Care into Oncology.

Current oncology (Toronto, Ont.)·2026
Same journal

Next-Generation Sequencing in Differentiated Thyroid Cancer Patients Treated with Lenvatinib: Results and Challenges in Real-Life Practice.

Current oncology (Toronto, Ont.)·2026
Same journal

The Route of Administration Determines the Efficacy of Zinc in Preventing Radiation-Induced Oral Mucositis: A Systematic Review and Meta-Analysis.

Current oncology (Toronto, Ont.)·2026
Same journal

Mechanisms of Progression and Challenges for Intervention in the Natural History of Early Prostate Cancer: A Narrative Review.

Current oncology (Toronto, Ont.)·2026
Same journal

Maintenance Therapy in Acute Myeloid Leukemia: Current Perspectives and Future Directions.

Current oncology (Toronto, Ont.)·2026
See all related articles

Related Experiment Video

Updated: Jun 8, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Intermittent versus continuous androgen suppression therapy: do we have consensus yet?

N C Buchan1, S L Goldenberg

  • 1The Vancouver Prostate Centre, Vancouver, BC.

Current Oncology (Toronto, Ont.)
|October 1, 2010
PubMed
Summary
This summary is machine-generated.

Intermittent androgen suppression (IAS) offers a potential alternative to continuous androgen deprivation therapy (ADT) for advanced prostate cancer, aiming to reduce side effects and costs. Ongoing studies will clarify its role in treatment.

Keywords:
Prostate cancerandrogen deprivation therapycontinuous androgen deprivationhormone therapyintermittent androgen therapy

Related Experiment Videos

Last Updated: Jun 8, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Area of Science:

  • Oncology
  • Urology

Background:

  • Androgen deprivation therapy (ADT) is a long-standing treatment for advanced prostate cancer.
  • Concerns exist regarding ADT's side effects, costs, and metabolic complications, particularly with earlier diagnosis and treatment initiation.
  • Intermittent androgen suppression (IAS) emerged as an alternative to mitigate these issues.

Purpose of the Study:

  • To evaluate the efficacy and potential benefits of intermittent androgen suppression (IAS) compared to continuous ADT.
  • To explore IAS as a strategy to reduce treatment-related side effects and healthcare costs in prostate cancer management.

Main Methods:

  • Review of preclinical evidence and Phase II/III clinical studies on IAS.
  • Analysis of treatment outcomes, including time to androgen independence, side effects, and cost-effectiveness.

Main Results:

  • Preclinical data suggest IAS may improve time to androgen independence.
  • Phase II and III studies have shown optimistic results for IAS.
  • IAS demonstrates potential for reduced complications and costs associated with ADT.

Conclusions:

  • IAS is gaining popularity globally as a therapeutic option for advanced prostate cancer.
  • Further large-scale prospective randomized trials are necessary to definitively establish the role of IAS in prostate cancer treatment protocols.